These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 26314389

  • 1. Peripheral blood eosinophils and other non-invasive biomarkers can monitor treatment response in eosinophilic oesophagitis.
    Schlag C, Miehlke S, Heiseke A, Brockow K, Krug A, von Arnim U, Straumann A, Vieth M, Bussmann C, Mueller R, Greinwald R, Bajbouj M.
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1122-30. PubMed ID: 26314389
    [Abstract] [Full Text] [Related]

  • 2. Serum eosinophil cationic protein is superior to mast cell tryptase as marker for response to topical corticosteroid therapy in eosinophilic esophagitis.
    Schlag C, Pfefferkorn S, Brockow K, Haller B, Slotta-Huspenia J, Schulz S, von Werder A, Ring J, Schmid RM, Bajbouj M.
    J Clin Gastroenterol; 2014 Aug; 48(7):600-6. PubMed ID: 24177377
    [Abstract] [Full Text] [Related]

  • 3. Longitudinal Evaluation of Noninvasive Biomarkers for Eosinophilic Esophagitis.
    Min SB, Nylund CM, Baker TP, Ally M, Reinhardt B, Chen YJ, Nazareno L, Moawad FJ.
    J Clin Gastroenterol; 2017 Feb; 51(2):127-135. PubMed ID: 27479142
    [Abstract] [Full Text] [Related]

  • 4. Normalized serum eosinophil peroxidase levels are inversely correlated with esophageal eosinophilia in eosinophilic esophagitis.
    Wright BL, Ochkur SI, Olson NS, Shim KP, Jacobsen EA, Rank MA, Dellon ES, Lee JJ.
    Dis Esophagus; 2018 Feb 01; 31(2):. PubMed ID: 29228243
    [Abstract] [Full Text] [Related]

  • 5. Serum eosinophilic cationic protein is correlated with food impaction and endoscopic severity in eosinophilic esophagitis.
    Cengiz C.
    Turk J Gastroenterol; 2019 Apr 01; 30(4):345-349. PubMed ID: 30945644
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.
    Dellon ES, Woosley JT, Arrington A, McGee SJ, Covington J, Moist SE, Gebhart JH, Tylicki AE, Shoyoye SO, Martin CF, Galanko JA, Baron JA, Shaheen NJ.
    Gastroenterology; 2019 Jul 01; 157(1):65-73.e5. PubMed ID: 30872104
    [Abstract] [Full Text] [Related]

  • 7. Utility of a Noninvasive Serum Biomarker Panel for Diagnosis and Monitoring of Eosinophilic Esophagitis: A Prospective Study.
    Dellon ES, Rusin S, Gebhart JH, Covey S, Higgins LL, Beitia R, Speck O, Woodward K, Woosley JT, Shaheen NJ.
    Am J Gastroenterol; 2015 Jun 01; 110(6):821-7. PubMed ID: 25781367
    [Abstract] [Full Text] [Related]

  • 8. Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis.
    Konikoff MR, Blanchard C, Kirby C, Buckmeier BK, Cohen MB, Heubi JE, Putnam PE, Rothenberg ME.
    Clin Gastroenterol Hepatol; 2006 Nov 01; 4(11):1328-36. PubMed ID: 17059896
    [Abstract] [Full Text] [Related]

  • 9. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis.
    Miehlke S, Hruz P, Vieth M, Bussmann C, von Arnim U, Bajbouj M, Schlag C, Madisch A, Fibbe C, Wittenburg H, Allescher HD, Reinshagen M, Schubert S, Tack J, Müller M, Krummenerl P, Arts J, Mueller R, Dilger K, Greinwald R, Straumann A.
    Gut; 2016 Mar 01; 65(3):390-9. PubMed ID: 25792708
    [Abstract] [Full Text] [Related]

  • 10. Increased numbers of eosinophils, rather than only etiology, predict histologic changes in patients with esophageal eosinophilia.
    Sridhara S, Ravi K, Smyrk TC, Kita H, Kephart GM, Weiler CR, Katzka DA.
    Clin Gastroenterol Hepatol; 2012 Jul 01; 10(7):735-41. PubMed ID: 22289868
    [Abstract] [Full Text] [Related]

  • 11. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.
    Dellon ES, Katzka DA, Collins MH, Hamdani M, Gupta SK, Hirano I, MP-101-06 Investigators.
    Gastroenterology; 2017 Mar 01; 152(4):776-786.e5. PubMed ID: 27889574
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
    Lucendo AJ, Miehlke S, Schlag C, Vieth M, von Arnim U, Molina-Infante J, Hartmann D, Bredenoord AJ, Ciriza de Los Rios C, Schubert S, Brückner S, Madisch A, Hayat J, Tack J, Attwood S, Mueller R, Greinwald R, Schoepfer A, Straumann A, International EOS-1 Study Group.
    Gastroenterology; 2019 Jul 01; 157(1):74-86.e15. PubMed ID: 30922997
    [Abstract] [Full Text] [Related]

  • 13. Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme.
    Miehlke S, Schlag C, Lucendo AJ, Biedermann L, Vaquero CS, Schmoecker C, Hayat J, Hruz P, Ciriza de Los Rios C, Bredenoord AJ, Vieth M, Schoepfer A, Attwood S, Mueller R, Burrack S, Greinwald R, Straumann A, International EOS-2 Study Group.
    United European Gastroenterol J; 2022 Apr 01; 10(3):330-343. PubMed ID: 35412032
    [Abstract] [Full Text] [Related]

  • 14. Dietary treatment modulates mast cell phenotype, density, and activity in adult eosinophilic oesophagitis.
    Arias Á, Lucendo AJ, Martínez-Fernández P, González-Castro AM, Fortea M, González-Cervera J, Yagüe-Compadre JL, Mota-Huertas T, Vicario M.
    Clin Exp Allergy; 2016 Jan 01; 46(1):78-91. PubMed ID: 25640519
    [Abstract] [Full Text] [Related]

  • 15. Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses From a 12-Week, Phase 2, Randomized, Placebo-controlled Trial.
    Collins MH, Dellon ES, Katzka DA, Hirano I, Williams J, Lan L.
    Am J Surg Pathol; 2019 Nov 01; 43(11):1501-1509. PubMed ID: 31498177
    [Abstract] [Full Text] [Related]

  • 16. A New Formulation of Oral Viscous Budesonide in Treating Paediatric Eosinophilic Oesophagitis: A Pilot Study.
    Oliva S, Rossetti D, Papoff P, Tiberti A, Rossi P, Isoldi S, Amil Dias J, Lucarelli S, Cucchiara S.
    J Pediatr Gastroenterol Nutr; 2017 Feb 01; 64(2):218-224. PubMed ID: 27253660
    [Abstract] [Full Text] [Related]

  • 17. Elevated Tryptase in EoE Is an Independent Phenomenon Associated with Extra-Esophageal Symptoms.
    Kutty GR, Downs-Kelly E, Crispin HT, Peterson KA.
    Dig Dis Sci; 2019 Jan 01; 64(1):152-157. PubMed ID: 30267171
    [Abstract] [Full Text] [Related]

  • 18. Clinical Features at Baseline Cannot Predict Symptom Response to Placebo in Patients With Eosinophilic Esophagitis.
    Hirano I, Dellon ES, Collins MH, Williams J, Lan L, Katzka DA.
    Clin Gastroenterol Hepatol; 2019 Sep 01; 17(10):2126-2128.e1. PubMed ID: 30502508
    [Abstract] [Full Text] [Related]

  • 19. Comparisons of Fluticasone to Budesonide in the Treatment of Eosinophilic Esophagitis.
    Albert D, Heifert TA, Min SB, Maydonovitch CL, Baker TP, Chen YJ, Moawad FJ.
    Dig Dis Sci; 2016 Jul 01; 61(7):1996-2001. PubMed ID: 27093866
    [Abstract] [Full Text] [Related]

  • 20. Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real-world efficacy from the EoE CONNECT registry.
    Laserna-Mendieta EJ, Navarro P, Casabona-Francés S, Savarino EV, Amorena E, Pérez-Martínez I, Guagnozzi D, Blas-Jhon L, Betoré E, Guardiola-Arévalo A, Pellegatta G, Krarup AL, Perello A, Barrio J, Gutiérrez-Junquera C, Teruel Sánchez-Vegazo C, Fernández-Fernández S, Naves JE, Oliva S, Rodríguez-Oballe JA, Carrión S, Espina S, Llorente Barrio M, Masiques-Mas ML, Dainese R, Feo-Ortega S, Martín-Dominguez V, Fernández-Pacheco J, Pérez-Fernández MT, Ghisa M, Maniero D, Nantes-Castillejo Ó, Nicolay-Maneru J, Suárez A, Maray I, Llerena-Castro R, Ortega-Larrodé A, Alcedo J, Granja Navacerrada A, Racca F, Santander C, Arias Á, Lucendo AJ, EUREOS and EoE CONNECT research group.
    United European Gastroenterol J; 2024 Jun 01; 12(5):585-595. PubMed ID: 38284792
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.